Invasive Meningococcal Disease

Not actual patients.

Meningococcal disease is uncommon, fast-moving, and potentially fatal1-3
 

  • Neisseria meningitidis is the major cause of invasive meningococcal disease (IMD)1
  • IMD is easily misdiagnosed4
  • IMD can progress rapidly to death in 24-48 hours4
  • More than 1 out of 3 survivors experience serious complications such as loss of limbs, hearing loss, and brain damage5
CDC recommendation icon

Of the 6 N. meningitidis serogroups—A, B, C, W, X, and Y—responsible for the most meningococcal disease worldwide, B, C, W, and Y circulate in the US.6

Missing vaccination icon

However, millions of teens and young adults are still missing vaccination against MenABCWY.7,8

Calendar with checkmark icon

By simplifying series completion and reducing the number of injections, a MenABCWY vaccine may help improve immunization rates and lower the burden of disease.9

While uncommon, meningococcal meningitis is a highly contagious infection.1,10

Some of the behaviors known to increase the risk of spreading the bacteria that cause IMD1,10:

Close quarters icon

Living in close quarters

Sharing food and beverage icon

Sharing drinks, utensils, and smoking devices

Coughing and sneezing icon

Coughing and sneezing

Kissing icon

Kissing

Smoking icon

Smoking

  • Among adolescents, 16- to 23-year-olds have the highest rates of meningococcal disease10-12
  • 1 in 10 individuals may be a carrier of the bacteria that causes IMD10,12,13
Vaccine icon

A combination MenABCWY vaccine may help streamline meningococcal vaccination for your patients and practice.9

Learn More

IMD=invasive meningococcal disease; MenABCWY=meningococcal serogroups A, B, C, W, Y.
 

Vaccination may not protect all recipients.

Indication & Important Safety Info

Indications for PENMENVY, BEXSERO, and MENVEO

Important Safety Information for PENMENVY, BEXSERO, and MENVEO

Indications for PENMENVY, BEXSERO, and MENVEO

PENMENVY is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y in individuals 10 through 25 years of age.

 

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

 

MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55 years of age. MENVEO does not prevent N. meningitidis serogroup B infections.

Important Safety Information for PENMENVY, BEXSERO, and MENVEO

  • Do not administer PENMENVY to individuals with a severe allergic reaction (e.g., anaphylaxis) to a previous dose of PENMENVY, to any component of this vaccine, or to any other diphtheria toxoid-containing vaccine
  • Do not administer BEXSERO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of BEXSERO or after a previous dose of BEXSERO
  • Do not administer MENVEO to individuals with a severe allergic reaction (e.g., anaphylaxis) to a previous dose of MENVEO, to any component of MENVEO, or to any other diphtheria toxoid-containing vaccine
  • Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of PENMENVY, BEXSERO, or MENVEO
  • For BEXSERO, the tip cap of the prefilled syringe may or may not be made with natural rubber latex. Natural rubber latex may cause allergic reactions. Please check the carton
  • Syncope (fainting) has occurred in association with administration of PENMENVY, BEXSERO, or MENVEO. Ensure procedures are in place to avoid injury from falling associated with syncope
  • PENMENVY, BEXSERO, or MENVEO may not protect all vaccine recipients, and PENMENVY or BEXSERO may not protect against all meningococcal serogroup B strains
  • Immunocompromised persons and some individuals receiving immunosuppressant therapy may have reduced immune responses to PENMENVY, BEXSERO, or MENVEO
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by N. meningitidis serogroups A, B, C, W, and Y, even if they develop antibodies following vaccination with PENMENVY, BEXSERO, or MENVEO
  • Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision to administer PENMENVY or MENVEO to individuals with a history of GBS should take into account the expected benefits and potential risks
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. A decision about when to administer MENVEO to an infant born prematurely should be based on consideration of the individual infant’s medical status and the potential benefits and possible risks of vaccination
  • For PENMENVY, the most commonly reported (≥10%) solicited adverse reactions in individuals aged 10 through 25 years after Dose 1 and Dose 2, respectively, were pain at the injection site (92% and 88%), fatigue (51% and 42%), headache (42% and 36%), myalgia (15% and 12%), nausea (15% and 10%), erythema (13% and 12%), and swelling (13% and 12%). The most commonly reported (≥10%) solicited adverse reactions in MenACWY conjugate vaccine-experienced individuals aged 15 through 25 years after Dose 1 and Dose 2, respectively, were pain at the injection site (80% and 74%), headache (41% and 33%), fatigue (40% and 33%), myalgia (15% and 13%), and nausea (15% and 12%)
  • For BEXSERO, the most commonly reported (≥10%) solicited adverse reactions in a Phase 3 clinical trial were pain at the injection site (87%-92%), fatigue (45%-49%), headache (37%-41%), nausea (11%-13%), erythema (10%-15%), myalgia (10%-14%), and swelling (10%-14%)
  • Common solicited adverse reactions with MENVEO among children initiating vaccination: at 2 months of age and receiving the four-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, vomiting, and diarrhea; at 7 months through 23 months of age and receiving the two-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, and diarrhea; at 2 through 10 years of age who received MENVEO were injection site pain, erythema, irritability, induration, sleepiness, malaise, and headache. Common solicited adverse reactions among adolescents and adults aged 11 through 55 years who received a single dose of MENVEO were pain at the injection site, headache, myalgia, malaise, and nausea. Across all age groups, some events were severe. Similar rates of solicited adverse reactions among adolescents and adults were observed following a single booster dose
  • For MENVEO, in two clinical studies, there were no notable differences in frequency and severity of solicited adverse reactions in individuals who received MENVEO 1-vial presentation compared to individuals who received the 2-vial presentation

 

Prescribing Information for PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine)

 

Prescribing Information for BEXSERO (Meningococcal Group B Vaccine)

 

Prescribing Information for MENVEO [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine]

To report SUSPECTED ADVERSE REACTIONS, contact GSK at gsk.public.reportum.com or
1-888-825-5249, or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

References

  1. Mayo Clinic. Meningitis. Reviewed October 17, 2024. Accessed January 14, 2025. https://www.mayoclinic.org/diseases-conditions/meningitis/symptoms-causes/syc-20350508

  2. Mbaeyi S, Duffy J, McNamara LA. Meningococcal disease. In: Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 14th ed. Washington, DC: Public Health Foundation; 2021:207-224. https://www.cdc.gov/vaccines/pubs/pinkbook/mening.html

  3. Rubis A, Schillie S. Chapter 8: meningococcal disease. In: Roush SW, Baldy LM, Mulroy J, eds. Manual for the Surveillance of Vaccine-Preventable Diseases. National Center for Immunization and Respiratory Diseases. October 30, 2024. Accessed January 6, 2025. https://www.cdc.gov/surv-manual/php/table-of-contents/chapter-8-meningococcal-disease.html

  4. Pelton SI. Meningococcal disease awareness: clinical and epidemiological factors affecting prevention and management in adolescents. J Adolesc Health. 2010;46(2):S9-S15. doi:10.1016/j.jadohealth.2009.11.220

  5. Parikh SR, Campbell H, Bettinger JA, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81(4):483-498. doi:10.1016/j.jinf.2020.05.079

  6. Centers for Disease Control and Prevention. Emergency preparedness and response. Increase in invasive serogroup Y meningococcal disease in the United States. Reviewed March 28, 2024. Accessed January 14, 2025. https://emergency.cdc.gov/han/2024/han00505.asp

  7. U.S. Census Bureau. Current population survey, annual social and economic supplement, 2019. Washington, DC: U.S. Census Bureau, Population Division; 2020. Accessed November 1, 2024. https://www2.census.gov/programs-surveys/demo/tables/age-and-sex/2019/age-sex-composition/2019gender_table1.xlsx

  8. Pingali C, Yankey D, Chen M, et al. National vaccination coverage among adolescents aged 13–17 years — National Immunization Survey-Teen, United States, 2023. MMWR. 2024;73(33):708-714. doi:10.15585/mmwr.mm7333a1

  9. Bekkat-Berkani R, Fragapane E, Preiss S, et al. Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB. J Infect. 2022;85(5):481-491. doi:10.1016/j.jinf.2022.09.001

  10. Burman C, Serra L, Nuttens C, Presa J, Balmer B, York L. Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination. Hum Vaccin Immunother. 2019;15(2):459-469. doi:10.1080/21645515.2018.1528831

  11. Centers for Disease Control and Prevention. Meningococcal disease. Risk factors for meningococcal disease. February 1, 2024. Accessed February 4, 2025. https://www.cdc.gov/meningococcal/risk-factors/index.html

  12. Vetter V, Baxter R, Denizer G, et al. Routinely vaccinating adolescents against meningococcus: targeting transmission & disease. Expert Rev Vaccines. 2016;15(5):641-658. doi:10.1586/14760584.2016.1130628

  13. Centers for Disease Control and Prevention. About meningococcal disease. February 1, 2024. Accessed July 29, 2024. https://www.cdc.gov/meningococcal/about/index.html